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Abstract
Background: Microglial cell activation and cerebral function impairment are described in both chronic hepatitis C viral (HCV)
and Human-Immune-Deficiency viral (HIV) infections. The aim of this study was to investigate the effect of acute HCV
infection upon cerebral function and microglial cell activation in HIV-infected individuals.
Methods: A case-control study was conducted. Subjects with acute HCV and chronic HIV coinfection (aHCV) were compared
to matched controls with chronic HIV monoinfection (HIVmono). aHCV was defined as a new positive plasma HCV RNA
within 12 months of a negative RNA test. Subjects underwent neuro-cognitive testing (NCT), cerebral proton magnetic
resonance spectroscopy (1H-MRS) and positron emission tomography (PET) using a 11C-radiolabeled ligand (PK11195),
which is highly specific for translocator protein 18 kDA receptors on activated microglial cells. Differences between cases
and controls were assessed using linear regression modelling.
Results: Twenty-four aHCV cases completed NCT and 1H-MRS, 8 underwent PET. Of 57 HIVmono controls completing NCT,
12 underwent 1H-MRS and 8 PET. Subjects with aHCV demonstrated on NCT, significantly poorer executive function (mean
(SD) error rate 26.50(17.87) versus 19.09(8.12), p= 0.001) and on 1H-MRS increased myo-inositol/creatine ratios (mI/Cr, a
marker of cerebral inflammation) in the basal ganglia (ratio of 0.71(0.22) versus 0.55(0.23), p= 0.03), compared to subjects
with HIVmono. On PET imaging, no difference in 11C-PK11195 binding potential (BP) was observed between study groups
(p.0.10 all cerebral locations), however lower BPs were associated with combination antiretroviral therapy (cART) use in the
parietal (p= 0.01) and frontal (p= 0.03) cerebral locations.
Discussion: Poorer cognitive performance and disturbance of cerebral metabolites are observed in subjects with aHC,V
compared to subjects with HIVmono. Higher 11C-PK11195 BP was not observed in subjects with aHCV, but was observed in
subjects not on cART.
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Introduction
Central nervous system disturbances are well described in
patients with chronic HIV infection and more recently, in those
with chronic hepatitis C (HCV) infection in the absence of
significant liver disease[1–3]. Abnormalities, compared to matched
control populations, demonstrable using cerebral function mea-
sures such as neurocognitive testing (NCT) and proton magnetic
resonance spectroscopy (1H MRS) have been shown in both
patient groups [4,5]. Such cerebral deficits may be greater in
individuals coinfected with HIV and chronic HCV, compared to
individuals with HIV monoinfection [6–9]. Both viruses can be
identified in cerebrospinal fluid and brain tissue [9–11] and
although the pathophysiology of these cerebral disturbances
remain unclear, microglial cell activation has been proposed as a
promoter of neurodegeneration and inflammation in both HIV-
associated encephalopathy [12] and chronic HCV-associated
cognitive decline [13].
The isoquinoline PK11195 is a highly specific, high-affinity
ligand for translocator protein 18 kDA receptors on activated
microglial cells. PK11195 can be radio-labeled with carbon 11
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(11C) and injected as a tracer during cerebral positron emission
tomography (PET) scanning to provide non-invasive, quantifica-
tion of microglial cell activity at a cellular level. This technique has
been histologically validated in animals [14,15] and humans [16]
and used to demonstrate microglial activation in a variety of
human neurological disorders, including in patients with chronic
HCV in the presence or absence of cirrhosis [17–20]. To date,
increased binding of PK11195 has been demonstrated only in
HIV-infected subjects with severe HIV encephalopathy [21], with
increased binding not reported in asymptomatic HIV-infected
subjects or in those with mild cognitive deficits [22].
The impact of acute HCV infection acquisition upon cerebral
function parameters remains poorly understood. Secondary to a
recent epidemic of acute HCV infection in HIV-infected men who
have sex with men, this phase of infection is now frequently
identified in clinical practice [23,24]. Earlier work from our group
[25] identified a reduction in inflammatory cerebral metabolites in
the basal ganglia of 10 subjects with acute HCV and chronic HIV
infection. The aim of this study, was to further elucidate any
changes in cerebral function observed in subjects during acute
HCV infection via the assessment of cognitive performance and
cerebral metabolites and to assess for any evidence of increased
microglial cell activation via PET imaging.
Methods
Ethics approval was obtained from the National Research
Ethics Service in separate applications to undertake the NCT
studies (07/H0803/128) and 1H MRS (08/H0712/15). For the
administration of 11C PK11195 (09/H0712/17) permission was
also obtained from the Administration of Radioactive Substances
Advisory Committee (ARSAC) of the UK. All participants
provided written, informed consent prior to commencing any
study procedures.
All subjects completed NCT studies with a sub-set enrolled in
1H-MRS and a smaller group undergoing PET examination. All
subjects were recruited during routine HIV clinic attendances
and were eligible if aged over 18 years with chronic HIV
infection (HIV-1 antibody positive for a minimum of 6 months).
Exclusion criteria included current AIDS-defining illnesses, any
active neurological complaint or disease, encephalopathy,
untreated syphilis, chronic hepatitis B infection, current receipt
of interferon and ribavirin treatment, hepatic synthetic functional
impairment (a serum albumin below 30 g/dL or prolonged
prothrombin time), use of benzodiazepines or recreational drugs
within the past month and alcohol consumption in excess of an
average of 20 g/day in the past six months.
Selection of Subjects with Acute Hepatitis C
Subjects with HIV/acute HCV coinfection (aHCV cases) were
required to have acute HCV, defined by a new positive plasma
HCV RNA test within 12 months of a negative HCV RNA test.
Selection of Control Subjects
HIV-infected individuals without hepatitis C co-infection
(HIVmono), were recruited as control subjects. All were required
to be HCV antibody or RNA negative within the past year, with
normal liver function tests thereafter. For participants undergoing
1H-MRS and PET, subjects were matched to aHCV cases
according to age, time-elapsed since HIV diagnosis, current
CD4+ cell count, whether currently receiving combination
antiretroviral therapy (cART), and type of cART in those
receiving therapy (non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based or protease inhibitor (PI)-based).
Neurocognitive Test (NCT)
A computerised assessment of cognitive performance was
undertaken (CogStateTM, Melbourne, Australia) which has been
previously validated in HIV infection [26] and used in HIV
treatment studies [27]. It assesses 8 cognitive domains (psycho-
motor function, identification, monitoring and matched learning;
associate learning, visual learning and working memory; and
executive function). Overall cognitive speed, performance accura-
cy, executive function and composite Z-scores were then
calculated for each subject.
Proton Magnetic Resonance Spectroscopy (1H-MRS)
1H-MRS was performed on an AchievaTM 1.5 Tesla scanner
(Phillips NV, Best, Netherlands) at the Robert Steiner Magnetic
Resonance Unit, Hammersmith Hospital, London, UK. Exami-
nation included sagittal, coronal and axial T1-weighted images of
the brain and T2-weighted axial double spin echo images.
1H-
MRS was performed in 3 voxel locations: frontal white matter
(FWM), frontal grey matter (FGM) and the basal ganglia (BG),
using a double spin echo point resolved spectroscopy (PRESS)
sequence with the following settings: echo time (TE) 36 ms,
repetition time (TR) 3000 ms, 2048 data points, spectral width of
2500 Hz and 128 data acquisitions. MR spectra were post-
processed for automated water signal suppression and water
shimming. T1 and T2-weighted MR images were studied by a
neuroradiologist. All spectra were analysed and quantified by one
observer (LG) using a java-based version of the magnetic
resonance user interface package (jMRUI Version Number: 3.0)
[28], incorporating the AMARES algorithm [29] and metabolites
expressed as ratios to cerebral creatine (Cr).
Cerebral PET with 11C Labelled PK11195
For subjects undergoing PET scanning, a strict 1:1 matching
process of cases to controls was applied according to the selection of
subjects above using the following criteria for matching; all gender
matched, age (within 5 years), elapsed time since HIV diagnosis
(within 5 years), current CD4+ count (within 100 cells/uL), nadir
CD4+ count (within 100 cells/uL), whether currently receiving
cART and type of cART (NNRTI or PI-based regimens matched).
PET scanning was performed on a PET-CT scanner (Whole
body positron emission tomograph GE Discovery Rx PET/CT,
GE Healthcare, Waukesha, Wisconsin) at the MRC Cyclotron
Building, Hammersmith Hospital, Imperial College, London. A
transmission CT scan and emission scan were performed with
subjects lying in a partially-enclosed PET scanner and an injection
of 11C-labeled PK11195 radioactive ligand [R-enantiomer] was
given as a smooth bolus. The target quantity was 296 MBq
(8.00 mCi, approximately 1.7mSv tissue dose). Parametric images
of specific 11C –[R]-PK11195 binding potential (BP), a measure
reflecting Bmax/Kd, were calculated using a basis function
implementation of a simplified reference tissue model [30]. The
possible widespread expression of TSPO in patients with viral
infections makes it difficult to select a reference region representing
nonspecific PK uptake in the brain. We therefore used a
supervised clustering procedure to identify reference clusters of
voxels in the grey matter having PK11195 time activity curves
mirroring those of a standardized control population, as previously
described [31].
For each patient, PK11195 BP values in the parietal, occipital,
frontal, temporal, ventral striatum, caudate, putamen and
thalamus regions were calculated by applying standardised object
maps to normalized 11C-[R]-PK11195 BP images in Analyze
software (Analyze AVW, Mayo Clinic, US). Spatial normalization
of parametric images into standard stereotaxic space (Montreal
Cerebral Function in Acute HCV/HIV Coinfection
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Neurologic Institute, MNI) was achieved by normalizing the
individual MRI T1 image to the T1 image template in MNI space
available in SPM5 software (http://www.fil.ion.ucl.ac.uk/spm/
software/spm5/) and then applying the transformation parameters
to the respective BP images previously co-registered to the
individual MRI T1 image.
Statistical Analysis
Univariate linear regression analysis was used to investigate the
presence of association between cerebral function assessments in
each study (NCT scores, 1H-MRS cerebral metabolite ratios and
PK11195 BP) and study group. Where significant differences were
found, linear regression analysis was used to investigate association
between assessment results and clinical parameters. Any significant
baseline parameter discrepancy between groups or associated
factors with a significance of p,0.15 were taken forward to
multivariate analysis. SPSS version 18.0 was used for analysis. p-
values of ,0.05 were considered statistically significant.
Results
Baseline Characteristics
Overall, 81 subjects completed NCT procedures with baseline
characteristics described in Table 1. A significantly lower propor-
tion of the aHCV group were receiving cART than in the HIVmono
group (71% versus 95% respectively, p=0.006). All aHCV subjects
had detectable HCV viraemia and elevated transaminases at the
time of study entry and had a documented, previously negative
HCV RNA test within a median of 24 weeks (range 4–48). No
subject had impaired hepatic synthetic function or hepatic failure.
Neurocognitive Testing Results
No significant differences were observed in overall composite Z-
score or performance accuracy between study groups (p$0.05 all
observations, Table 2). However individuals with aHCV had
significantly poorer executive function performance than HIVmono
in the univariate analysis (p = 0.02, 95%CI 0.09, 1.07). When
factors associated with poorer executive function were examined
in a multivariate model, no association with receiving cART was
observed (p=0.37, 95%CI 218.8, 7.1), however lower nadir
CD4+ cell count and aHCV study group were independently
associated with poorer executive function performance (Table 3). In
the univariate analysis, aHCV was associated with faster cognitive
speed, but in the multivariate analysis, after adjustment for age,
cART status, nadir and current CD4+ cell count, this association
was no longer statistically significant (Table 3).
1H-MRS
Twenty-four aHCV subjects and 12-matched HIVmono subjects
also underwent cerebral 1H-MRS. Subjects were matched accord-
ing to age, gender and cART status. All 36 participants were male.
Mean(SD) age and proportion receiving cART for aHCV and
HIVmono were 40(8) versus 44(12) years and 71% versus 75%
respectively. The mean (SD) time elapsed since last negative plasma
HCV RNA in the aHCV patients prior to 1H-MRS was 24 weeks.
Cerebral metabolite ratios demonstrated a trend towards higher
mI/Cr ratios in the basal ganglia (BG) of aHCV subjects (p=0.06,
95% CI for difference between groups20.01, 0.32, see Table 2). In
a multivariate model, both nadir CD4 count and aHCV study
group were independently associated with higher mI/Cr (p= 0.05
and p= 0.03 respectively, Table 3). No significant associations were
observed between BG mI/Cr and clinical parameters including
the time elapsed since HCV RNA negative test, age or current
CD4+ count (p-value.0.45 all values). Of note in subjects with
aHCV, a strong association between higher BG mI/Cr and poorer
executive function was observed (p= 0.006, 95%CI 0.00, 0.01).
Cerebral PET with 11C Labelled PK11195
16 subjects (8 in each group) then underwent a PET
examination with all cases and controls matched for gender (all
male) and HIV disease characteristics; numbers receiving no
Table 1. Patient demographics, clinical parameters and study participation of subjects completing neurocognitive testing (NCT)
procedures.
Study
Participation Clinical parameter
Acute HCV/HIV
(aHCV)
HIV monoinfection
(HIVmono)
Difference between
groups, p-value*
Overall Number, n 24 57
Age (years), median [IQR] 41 [36,44] 47 [39, 56] 0.003
Male gender, n (%) 24 (100) 50 (89) 0.10
Time-elapsed since HIV diagnosis (years), median [IQR] 6 [3,12] 11 [5,16] 0.02
Current CD4+(cells/mL), median [IQR] 590 [458, 745] 505 [382, 783] 0.29
Nadir CD4+(cells/mL), median [IQR] 200 [215, 395] 205 [88, 283] 0.01
Receiving antiretroviral therapy, n (%) 17 (71) 54 (95) 0.006
Current plasma HIV viral load below 50 c/mL, n (%) 16 (67){ 54 (95) 0.002
HIV viral load of remaining subjects (c/mL), median [IQR] 5797 [1136, 11758] 14182 [1095, 15952] 0.18
Time elapsed since negative HCV RNA test (weeks),
median [IQR]
24 [20,32] – –
Current ALT (IU), median [IQR] 213 [78, 237] – –
Peak ALT (IU), median [IQR] 237 [180, 820] – –
HCV genotype 1, n (%) 21 (88) – –
Most recent HCV RNA (c/mL), median [IQR] 986855 [56650, 4315528] – –
Table 1 legend: HCV = hepatitis C virus; RNA: ribonucleic acid; ALT = alanine aminotransferase; IU = international units;
{1 subject had VL 87 copies/mL at time of assessment, repeat ,50 copies/mL, *using Fisher’s exact test or t-test].
doi:10.1371/journal.pone.0038980.t001
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cART, NNRTI-based and boosted PI-based cART were 2, 4 and
2 subjects in each group, respectively. The mean number of weeks
elapsed since most recent negative plasma HCV RNA test in this
smaller aHCV sub-group was 20.5 (range 16–28) indicating very
recent acquisition in all subjects.
The reference regions were within the cortex and no patterns
were observed in their extent/location. No overlap with reference
regions and regions of interest occurred. Overall PK11195 BPs for
each cerebral region of interest are shown in Table 2. No
significant difference between aHCV cases and controls was
observed in any location (p.0.10 all values), but in the
multivariate analysis, receiving cART was independently associ-
ated with significantly lower PK11195 BP in the frontal (p = 0.05,
95% CI 20.82, 0.02) and parietal locations (p = 0.03, 95%CI
20.14, 20.01), see Table 4 and Figure 1).
Discussion
In this study, we have demonstrated that acquisition of acute
HCV in HIV-infected subjects is associated with changes in
cerebral function measures using a cognitive assessment and
cerebral 1H-MRS. We did not however, demonstrate significant
differences in PK11195 BP when using PET imaging as an in vivo
marker of microglial cell activation.
Acute HCV was independently associated with poorer executive
function performance in this study, despite the relatively well-
preserved CD4+ cell counts and young age of subjects enrolled.
Importantly, these differences remained statistically significant
after adjustment for the lower proportion of aHCV subjects
receiving cART. While this form of higher cognitive processing
has previously been described in HIV and chronic HCV/HIV
coinfection [6,32], it has not previously been associated with the
acute phase of HCV. These findings suggest that a neurological
disturbance involving the prefrontal cortex and fronto-striatal
regions may occur, in a similar manner to chronic HIV infection
[33,34]. Aside from nadir CD4+ cell count, no association with
executive function and other clinical parameters were found as an
alternative explanation, supporting acute HCV viraemia as the
potential cause of this deficit. Unfortunately, without cognitive
assessment data which precedes HCV acquisition, it is not possible
to confirm these findings reflect an acute deterioration in cognitive
performance associated with the acquisition of HCV infection.
Table 2. Results of cerebral function assessments and univariate regression analysis to investigate differences between subject
groups.
Cerebral function
assessment,
mean (SD)
Acute
HCV/HIV
(aHCV)
HIV
monoinfection
(HIVmono) p-value [95%CI]
NCT Number of participants, n 24 57
Participants on cART, n(%) 17 (71%) 54 (95%)
Cognitive speed (logms) 10.57 (0.28) 10.73 (0.33) 0.05 [20.99, 0.01]
Accuracy (arc.proportion correct) 3.00 (0.26) 2.88 (0.42) 0.20 [20.18, 0.83]
Executive function (error rate) 26.50 (17.87) 19.09 (8.12) 0.02 [0.09, 1.07]
Composite Z-score 0.16 (2.27) 20.08 (2.25) 0.68 [20.90, 1.38]
1H-MRS Number of participants, n 24 12
Participants on cART, n(%) 17 (71%) 9 (75%)
Frontal grey matter NAA/Cr 1.42 (0.25) 1.35 (0.10) 0.32 [20.41, 1.21]
Cho/Cr 0.59 (0.12) 0.63 (0.17) 0.31 [22.38, 0.77]
mI/Cr 0.70 (0.28) 0.62 (0.13) 0.39 [20.10, 0.25]
Frontal white matter NAA/Cr 1.53 (0.32) 1.48 (0.26) 0.63 [20.42, 0.68]
Cho/Cr 1.04 (0.20) 1.02 (0.19) 0.73 [20.69, 0.98]
mI/Cr 0.96 (0.48) 0.83 (0.54) 0.47 [20.23, 0.49]
Basal ganglia NAA/Cr 1.71 (0.25) 1.65 (0.29) 0.54 [20.45, 0.84]
Cho/Cr 0.77 (0.12) 0.80 (0.19) 0.36 [22.27, 0.85]
mI/Cr 0.71 (0.22) 0.55 (0.23) 0.06 [20.01, 0.32]
PK11195 BP Number of participants, n 8 8
Participants on cART, n(%) 6 (75%) 6 (75%)
Ventral striatum 0.18 (0.10) 0.22 (0.13) 0.45 [23.46, 1.64]
Caudate 0.08 (0.04) 0.09 (0.08) 0.69 [25.76, 3.94]
Putamen 0.21 (0.11) 0.28 (0.14) 0.29 [23.49, 1.14]
Thalamus 0.52 (0.31) 0.55 (0.17) 0.84 [21.44, 1.19]
Parietal 0.07 (0.06) 0.10 (0.06) 0.33 [27.56, 2.71]
Temporal 0.13 (0.03) 0.16 (0.05) 0.16 [210.82, 1.99]
Occipital 0.13 (0.04) 0.19 (0.09) 0.10 [26.58, 0.54]
Frontal 0.83 (0.40) 1.03 (0.27) 0.26 [21.34, 0.40]
[Legend Table 2: FGM= frontal grey matter; FWM= frontal white matter; BG = basal ganglia; NAA =N-acetyl aspartate; Cr = creatine; Cho = choline; mi =myo-inositol peak].
doi:10.1371/journal.pone.0038980.t002
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Statistically significantly greater mI/Cr ratios were observed in
the BG of subjects with acute HCV, when compared to matched
controls in our multivariate model. Proportions of subjects
receiving cART were very similar in both groups. mI is an
osmosensitive glial marker and plays a crucial role in cell volume
regulation [35]. The changes to mI/Cr ratio that were observed
may represent increased neuroinflammation and glial proliferation
during the early phase of HCV. Forton et al [36] have previously
described increases of mI/Cr ratio in patients with chronic HCV,
in the frontal white matter, rather than the BG. As the BG has a
higher blood flow per unit volume [37] than other cerebral
locations, it is possible that greater and earlier exposure of this
cerebral location may explain why the changes observed in our
study during acute infection had not yet evolved in other areas of
the brain. Furthermore, BG dysfunction is associated with
symptoms of fatigue and inertia in other neurological disorders
and therefore inflammatory changes in this location, may explain
the cognitive deficits we observed [38]. Interestingly and in
contrast, in our earlier pilot study, we reported reductions in BG
mI/Cr ratios in 10 subjects with acute HCV [25]. The changes we
now report within a larger cohort may reflect a time dependent
phenomena whereby dynamic changes in mI/Cr ratios are
occurring during the early course of acute HCV infection. In
our previous work, an average of 16 weeks had elapsed since most
recent negative HCV RNA result, suggesting very recent
acquisition of HCV virus. In this larger MRS study, the mean
time elapsed since last negative HCV RNA result was 24 weeks
and therefore we postulate these osmosensitive glial markers may
change rapidly during acute HCV infection. Alternatively, other
factors such as the small size of the earlier pilot study or differences
in HIV and cART parameters of the participants may be
responsible for these apparently contradictory findings.
No differences in PK11195 BP were observed between our study
groups. Several plausible explanations for these findings exist. First,
microglial cellsmaynotbeactivatedbyHCV in vivo,butanalternative
cell-type may be responsible, or indeed, CNS neurological distur-
bancemay not occur at all. Alternatively, microglial cell recruitment
may only take place during later stages of chronic HCV infection, as
the inflammatoryprocessmay take time todevelop, given thechronic
nature of HCV infection over many decades. The first theory is
Table 3. Results of univariate and multivariate analyses to examine clinical parameters associated with executive function
performance, composite speed and basal ganglia mI/Cr ratio.
Cerebral function
assessment result
Poorer
executive
function
Poorer
executive
function
Faster
Composite
speed
Faster
Composite
speed
Higher basal
ganglia
mI/Cr ratio
Higher basal
ganglia
mI/Cr ratio
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Clinical parameter p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI]
aHCV study group 0.02 [0.09, 1.07] 0.001 [5.8, 20.1] 0.05 [20.99, 0.00] 0.22 [20.3, 0.1] 0.06 [20.01, 0.32] 0.03 [0.02, 0.35]
Nadir CD4+ count,
per 100 cell/uL increase
0.09 [20.30, 0.02] 0.001 [20.1, 20.02] 0.03 [20.33, 20.02] 0.10 [20.01, 0.00] 0.09 [20.10, 0.01] 0.05 [20.11, 0.00]
Current CD4+ count,
per 100 cell/uL increase
0.70 [20.12, 0.08] 2 0.05 [20.20, 20.00] 0.78 [20.05, 0.03] 0.83 [20.05, 0.04] 2
Age, per 10 year increase 0.68 [20.28, 0.18] 0.59 [23.9, 2.2] 0.03 [0.02, 0.47] 0.20 [20.30, 1.30] 0.45 [20.12, 0.06] 2
Receiving cART 0.70 [20.95, 0.65 0.37 [218.8, 7.1] 0.42 [20.47, 1.12] 0.79 [20.34, 0.26] 0.58 [20.14, 0.24] 2
Plasma VL,
per 1000 c/mL increase
0.37 [20.38, 0.14] 0.06 [20.54, 0.01] 0.82 [20.01, 0.01] 0.59 [20.01, 0.01] 0.84 [20.01, 0.01] 2
Time since HIV diagnosis,
per 10 year increase
0.34 [20.06, 0.02] 0.15 [20.85, 0.13] 0.57 [20.03, 0.05] 0.54 [20.02, 0.01] 0.81 [21.58, 1.25] 2
doi:10.1371/journal.pone.0038980.t003
Table 4. Results of univariate and multivariate analyses to examine clinical parameters associated with occipital, parietal and
frontal PK11195 Binding Potential (BP).
Cerebral location
of PK11195
binding Potential (BP) Occipital Occipital Parietal Parietal Frontal Frontal
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Clinical parameter p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI] p-value [95% CI]
aHCV study group 0.10 [20.15, 0.01] 0.11 [20.13, 0.02] 0.33 [20.10, 0.03] 2 0.26 [20.58, 0.17] 2
Nadir CD4+ count,
per 100 cell/uL increase
0.65 [20.02, 0.03] 2 0.18 [20.01, 0.03] 2 0.24 [20.04, 0.14] 2
Current CD4+ count,
per 100 cell/uL increase
0.68 [20.02, 0.03] 2 0.06 [20.01, 0.03] 0.14 [20.01, 0.02] 0.13 [20.02, 0.17] 0.29 [20.04, 0.14]
Age, per 10 year increase 0.62 [20.05, 0.03] 2 0.48 [20.04, 0.02] 2 0.35 [20.87, 20.07] 2
Receiving cART 0.06 [20.19, 0.00] 0.07 [20.18, 0.09] 0.01 [20.15, 20.02] 0.03 [20.14, 20.01] 0.03 [20.87, 20.07] 0.05 [20.82, 0.02]
doi:10.1371/journal.pone.0038980.t004
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perhaps refuted and last theory supported by the findings of Grover
and colleagues who describe increased PK11195 BP, interpreted as
microglial cell activation, in patients with chronic HCV without
significant liver disease and by the findings of Cagnin and colleagues
who observed similarly increased PK11195 BP in a small number of
subjects with advanced, chronic HCV infection using the same PET
methodologies [36]. It is therefore feasible that during the acute
periodof infectionwithHCV,there isnochange to levelsofmicroglial
cell activation. It is known that microglia are recruited from
circulating macrophage/monocytes and animal model data have
demonstrated that this process may take several months following
cerebral insult [39]. The mean time elapsed since negative HCV
RNAtestwas21weeks inthe8aHCV subjectsof thisPETstudy,which
is likely tobeanover-estimationof actual time sinceviral transmission.
It is therefore possible, if our studywas repeated severalmonths later,
different results would be observed. Another explanation for our
findings is that due to ligand-factors including high plasma-protein
binding, non-specific binding or low brain uptake, PK11195 as a
neurotracer was insufficiently sensitive to detect subtle changes in
microglial activation in such neurologically asymptomatic subjects,
and thatuseofother,newlyavailable, alterative ligands including 11C
PBR-28[40], 11CDPA-713[41]or11CDAA-1106[42]mayalterour
findings. FurtherPETstudies areneeded toanswer thesequestions. If
microglial activation is a feature of the chronic phase of HCV
infection, we postulate that the effects of circulating cytokines (rather
than microglial cell activation) may be responsible for the cerebral
function differences we observed in this study. The neuropsycholog-
ical effects of endogenous circulating cytokines and chemokines are
observed in the presence of chronic infection and are very similar to
the CNS effects of therapeutically-administered interferon.
Interestingly, we observed an association between those receiving
cART and lower PK11195 BP values in some cerebral locations,
which has not been previously described and which suggests lower
levels of microglial cell activation in subjects receiving cART,
irrespective of acute HCV status. While only small numbers of
patientswere sampled and fewnumber of subjectswere not receiving
cART, this suggests that, similar to systemic levels of inflammation,
neuroinflammation may also be reduced in effectively treated HIV-
infected subjects. Over time, ongoing inflammation within the CNS
may result in progressive neuronal damage with subsequent clinical
sequelae and these data suggest an additional potential benefit from
cART, which although may be postulated, have not to date been
clearly demonstrated.
Associations between recreational drug use, concurrent sexually-
transmitted infections and acquisition of acute HCV have been
describedwhichmay influence cerebralmetabolite ratios and have a
negative impact upon cognitive performance [43]. For this reason,
any subjectwith recent recreational drugmisuse (withinpast 4weeks)
or current sexually transmitted infectionknown tocauseCNSdisease
(such as early syphilis) were excluded. It remains possible, however,
that high rates of historical drug misuse (with resultant cerebral
damage) may have contributed to our observations. A further
limitation of this work is the absence of longitudinal follow-up studies
to identify if any increaseof 11CPK11195BPevolveswithdurationof
HCV coinfection, although it should be noted that ethical consid-
erations on radiation dosage has precluded the evaluation of such
longitudinal PET studies to date. Finally, the sample size for the 1H-
MRS and PET imaging studies, limits our ability to detect subtle
differences and associations. PET scans with PK11195 are too costly
for large-scale studies, but our work is of similar size to previous
physiological PET studies and larger thanother previously published
work in this area.
In summary, we report changes to cerebral function measures in
subjects with acute HCV, but have not found differences of PK
11195 BP, representing microglial cell activation, in the early
months of HCV viraemia. If microglial activation is a late feature
of chronic HCV infection, then there may be an additional clinical
reason to treat and eliminate HCV in the acute phase where
possible, as therapy-response rates are higher and recommended
treatment courses shorter [44].
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